FLNA Stock Price | Filana Therapeutics, Inc. P/E, Revenue, EPS, & Forecasts

Filana Therapeutics, Inc. • FLNA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Filana Therapeutics, Inc.

Ticker

FLNA

Trading on

NASDAQ

ISIN

US14817C1071

Industry

Biotechnology

Sector

Healthcare

CEO

Richard Jon Barry

Headquarters

6801 N. Capital of Texas Highway, Austin, TX, United States, 78731

Employees

Website

filanatx.com

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Metrics

BasicAdvanced

Market cap

$39.4M

P/E ratio

EPS

-$0.87

Dividend Yield

0.00%

Beta

-0.66

Forward P/E ratio

151.52

EBIDTA

$-12.7M

Ex dividend date

2012-12-13

Price & volume

Market cap

$39.4M

Average daily volume

5.3M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

151.52

PEG ratio

1.62

Trailing P/E

Price to sales

2.54

Price to book

0.78

Earnings

EPS

-$0.87

EPS estimate (current quarter)

-$0.23

EPS estimate (next quarter)

-$0.25

EBITDA

$-12.7M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

-0.66

52-week High

$4.98

52-week Low

$0.67

50-day moving average

$0.88

200-day moving average

$1.49

Short ratio

23.68

Short %

13.14%

Management effectiveness

ROE (TTM)

-55.79%

ROA (TTM)

-7.14%

Profit margin

0.00%

Gross profit margin

$-15.7M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

48.3M

Float

46.9M

Insiders %

2.05%

Institutions %

26.81%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 2 analysts.

Average price target

$6.50

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.22

-$0.27

18.52%

Q3 • 25Beat

-$0.26

-$0.30

13.33%

Q4 • 25Beat

-$0.21

-$0.23

8.70%

Q1 • 26Beat

-$0.18

-$0.22

18.18%

Q2 • 26Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-10.3M

-∞%

Q1 • 26

$0M

$-8.6M

-∞%

Q2 • 26

NaN%

-16.73%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$108M

$40.2M

37.12%

Q1 • 26

$104M

$40.3M

38.78%

Q2 • 26

-4.12%

0.17%

4.47%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-8.9M

$-0.1M

$-8.9M

Q1 • 26

$-3.9M

$-0M

$-3.9M

Q2 • 26

-56.58%

-68.63%

-56.34%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Filana Therapeutics, Inc. share?

Filana Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does Filana Therapeutics, Inc. have?

Filana Therapeutics, Inc. currently has 48.3M shares.

Does Filana Therapeutics, Inc. pay dividends?

No, Filana Therapeutics, Inc. doesn't pay dividends.

What is Filana Therapeutics, Inc. 52 week high?

Filana Therapeutics, Inc. 52 week high is $4.98.

What is Filana Therapeutics, Inc. 52 week low?

Filana Therapeutics, Inc. 52 week low is $0.67.

What is the 200-day moving average of Filana Therapeutics, Inc.?

Filana Therapeutics, Inc. 200-day moving average is $1.49.

Who is Filana Therapeutics, Inc. CEO?

The CEO of Filana Therapeutics, Inc. is Richard Jon Barry.

How many employees Filana Therapeutics, Inc. has?

Filana Therapeutics, Inc. has 17 employees.

What is the market cap of Filana Therapeutics, Inc.?

The market cap of Filana Therapeutics, Inc. is $39.4M.

What is the P/E of Filana Therapeutics, Inc.?

The current P/E of Filana Therapeutics, Inc. is null.

What is the EPS of Filana Therapeutics, Inc.?

The EPS of Filana Therapeutics, Inc. is -$0.87.

What is the PEG Ratio of Filana Therapeutics, Inc.?

The PEG Ratio of Filana Therapeutics, Inc. is 1.62.

What do analysts say about Filana Therapeutics, Inc.?

According to the analysts Filana Therapeutics, Inc. is considered a buy.